Margetuximab Alternatives Compared
Margetuximab | Letrozole | Ibrance (palbociclib) |
|
---|
Margetuximab | Letrozole | Ibrance (palbociclib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Breast Cancer - Metastatic. Margetuximab may also be used for purposes not listed in this medication guide. |
Prescription only
Letrozole (brand name Femara) is a treatment that may be used to reduce the risk of breast cancer recurrence in postmenopausal women and also to increase the chance of ovulation in women with... View more |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Related suggestions Breast Cancer, Metastatic
|
|||||||||||||||
More about Margetuximab | More about Letrozole | More about Ibrance (palbociclib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Letrozole has an average rating of 6.5 out of 10 from a total of 367 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 21% reported a negative effect. |
Ibrance has an average rating of 6.8 out of 10 from a total of 85 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Margetuximab side effects |
View all Letrozole side effects |
View all Ibrance side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Letrozole prices |
View all Ibrance prices |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Margenza | Femara |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
460.8 hours |
48 hours |
29 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 9 drugs are known to interact with Margetuximab:
|
A total of 121 drugs are known to interact with Letrozole:
|
A total of 495 drugs are known to interact with Ibrance:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
July 25, 1997 |
February 03, 2015 |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.